(Interview between the two sessions) Zhang Guogang, member of the National Committee of the Chinese People’s Political Consultative Conference

  China News Service, Changsha, February 27 (Xiang Yipeng) "The national drug centralized procurement policy guides drug prices to return to a reasonable level, reducing the burden on the masses of drugs, but it needs to be more optimized." CPPCC member, Peasants and Workers Party Hunan Zhang Guogang, deputy chairman of the Provincial Party Committee and dean of the Third Xiangya Hospital of Central South University, said in an interview that the selection of centralized medicines should be combined with the latest clinical diagnosis and treatment standards, so that the common people can afford the medicines and can use them in time. Get a good medicine.

  Zhang Guogang introduced that in the past two years, the national drug centralized procurement reform has achieved breakthrough results. At present, the average price of the 112 products involved in the first three batches of nationally organized drug procurement has been reduced by 54%.

As of 2020, the actual purchase volume has reached 2.4 times the agreed purchase volume, saving more than 100 billion yuan in costs.

  Centralized procurement of drugs with volume is an important measure to coordinate the reform of the supply side of medical services.

Since the 19th National Congress of the Communist Party of China, in accordance with the decisions and deployment of the Party Central Committee and the State Council, the reform of centralized drug procurement has achieved remarkable results, and has played an important role in improving people's livelihood and welfare, promoting the reform of the three-medicine linkage, and promoting the healthy development of the pharmaceutical industry.

  However, Zhang Guogang found in his investigation that there are also many problems in the national drug centralized procurement.

For example, during the implementation of the national centralized drug procurement process, medical institutions found that centralized procurement products were out of line with clinical guidelines, the output of centralized procurement products was insufficient, and manufacturers stopped production and had net-packed specifications, etc., resulting in clinical shortages and people unable to use the most suitable drugs in time. .

  "Medicine is a subject that is constantly updated and iterative. The selection of centralized collection of drugs based on past clinical use has caused some national centralized procurement of drugs to lag behind the clinical diagnosis and treatment standards." Zhang Guogang took anti-hepatitis B virus drugs as an example. Lamivudine and adefovir dipivoxil tablets, but due to the high resistance rate of these two drugs, they are no longer used as a first-line treatment, but as a combination therapy for drug-resistant hepatitis B virus. The clinically applicable population is limited.

  In order to optimize the management of the national centralized procurement of drugs, Zhang Guogang suggested that the selection of national centralized procurement of drugs should be combined with the latest clinical diagnosis and treatment specifications, and the recommendations of clinical doctors and pharmacists should be extensively solicited to ensure that the selected species in centralized procurement are clinically used drugs.

At the same time, the centralized procurement of selected drugs will be included in clinical pathway management, medication guidelines will be formulated to promote the standardization of clinical diagnosis and treatment and rational use of drugs, so that more patients will benefit.

In addition, it is necessary to comprehensively evaluate the productivity and supply capacity of the national centralized drug production enterprises to solve the problem of intermittent shortage of drugs that causes patients to be unable to use drugs.

  "During the clinical diagnosis and treatment process, pharmacists assist in formulating dosing plans, conducting prescription/doctoral order review, monitoring and evaluating the efficacy and safety of drugs, ensuring the clinical safety and reasonable application of drugs." Zhang Guogang also said that pharmacists adopt various forms Preaching policies and drug knowledge to physicians and patients, and it is recommended to appropriately increase the fees and charges related to pharmacist services to enhance the stability of the pharmacist team. (Finish)